These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21557459)

  • 21. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
    Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
    Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
    Jan AS; Hosing C; Aung F; Yeh J
    Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
    Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
    Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
    Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
    Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A secondary CIBMTR analysis.
    Schoettler ML; Westbrook A; Watkins B; Stenger E; Qayed M; Chonat S; Williams KM
    Br J Haematol; 2024 Jul; 205(1):243-255. PubMed ID: 38817006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation.
    Arrabi L; Jan A; Hosing C; Milton DR; Yeh J
    Eur J Haematol; 2021 Dec; 107(6):634-641. PubMed ID: 34431142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
    Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
    Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
    Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
    Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
    Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
    Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.
    Epperla N; Hemauer K; Hamadani M; Friedman KD; Kreuziger LB
    Transfusion; 2017 Nov; 57(11):2775-2781. PubMed ID: 28836275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
    Abu Zaid M; Wu J; Wu C; Logan BR; Yu J; Cutler C; Antin JH; Paczesny S; Choi SW
    Blood; 2017 Jan; 129(2):162-170. PubMed ID: 27827824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
    Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
    Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis.
    Garming Legert K; Ringdén O; Remberger M; Törlén J; Mattsson J; Dahllöf G
    Oral Dis; 2021 Jul; 27(5):1217-1225. PubMed ID: 33012083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.
    Li A; Wu Q; Davis C; Kirtane KS; Pham PD; Sorror ML; Lee SJ; Gopal AK; Dong JF; Garcia DA; Weiss NS; R Hingorani S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):570-576. PubMed ID: 30940363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.